Arch Therapeutics, Inc. (ARTH)
OTCMKTS: ARTH · Delayed Price · USD
0.925
-0.085 (-8.42%)
May 3, 2024, 3:58 PM EDT - Market closed
Arch Therapeutics Revenue
Arch Therapeutics had revenue of $115.33K in the twelve months ending December 31, 2023, with 569.83% growth year-over-year. Revenue in the quarter ending December 31, 2023 was $45.87K with 632.58% year-over-year growth. In the fiscal year ending September 30, 2023, Arch Therapeutics had annual revenue of $75.72K with 383.80% growth.
Revenue (ttm)
$115.33K
Revenue Growth
+569.83%
P/S Ratio
38.04
Revenue / Employee
$14,416
Employees
8
Market Cap
4.39M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2023 | 75.72K | 60.07K | 383.80% |
Sep 30, 2022 | 15.65K | 4.09K | 35.34% |
Sep 30, 2021 | 11.57K | - | - |
Sep 30, 2020 | 0 | - | - |
Sep 30, 2019 | 0 | - | - |
Sep 30, 2018 | 0 | - | - |
Sep 30, 2017 | 0 | - | - |
Sep 30, 2016 | 0 | - | - |
Sep 30, 2015 | 0 | - | - |
Sep 30, 2014 | 0 | - | - |
Sep 30, 2013 | 0 | - | - |
Sep 30, 2012 | 0 | - | - |
Sep 30, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 81.80B |
Merck & Co. | 60.12B |
AbbVie | 54.40B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
ARTH News
- 6 months ago - Arch Therapeutics Provides Year End Operational Update - GlobeNewsWire
- 6 months ago - Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall) - GlobeNewsWire
- 8 months ago - Arch Therapeutics Provides AC5® Commercialization Update - GlobeNewsWire
- 8 months ago - Arch Therapeutics Completes Financing as Bridge to Uplisting - GlobeNewsWire
- 1 year ago - Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”) - GlobeNewsWire
- 1 year ago - Dedicated HCPCS Billing Code for Arch Therapeutics' AC5® Advanced Wound System Now In Effect - GlobeNewsWire
- 1 year ago - Arch Therapeutics' AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services - GlobeNewsWire
- 1 year ago - Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities - GlobeNewsWire